What this is
- How it works
- How it works isn't classified yet
- Tested for
- Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Main trialPhase 1
- “In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients…”In the company’s words, NCT06817343 on ClinicalTrials.gov
Other drugs for Neovascular Age-Related Macular Degeneration (nAMD)
- Surabgene LomparvovecAbbVie · Phase 3
- 4D-150 IVT4D Molecular Therapeutics · Phase 3
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- ElamipretideStealth BioTherapeutics Inc. · Phase 3
- ONS-5010Outlook Therapeutics, Inc. · Phase 3
Coming up1
- Feb 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Feb 2029 | A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) | |
| Phase 1Completed | 16 Feb 2026 | A Study of EXG102-031 in Patients With wAMD (Everest) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026